MedPath

2D vs 3D Planning for High-Dose Rate (HDR) Gynecological Brachytherapy

Phase 2
Completed
Conditions
Endometrial Cancer
Cervix Cancer
Interventions
Other: 2D HDR planning
Other: 3D HDR planning
Registration Number
NCT02091050
Lead Sponsor
AC Camargo Cancer Center
Brief Summary

Demonstrate the limitations of conventional dosimetry (2D) for the adjuvant brachytherapy treatment and assess whether tridimensional dosimetry relates more faithfully with the occurrence of adverse effects.

Detailed Description

Radiotherapy is part of a multidisciplinary strategy to fight cancer in all stages, using ionizing radiation to cause damage in tumor cells. After radical surgical treatment of gynecological tumors, pathological findings, such as extension of the myometrium invasion, histologic grade, and vascular- lymphatic invasion predict the risk of locoregional recurrence of disease and, consequently, the need for adjuvant treatment. There are two main methods of adjuvant therapy after hysterectomy for malignant neoplasm of the cervix or endometrium: external beam radiotherapy with or without booster dose of vaginal vault brachytherapy or brachytherapy alone. There are few data in the literature and clinical experience with brachytherapy dimensional (3D) for adjuvant treatment of vaginal vault .

Objective: To demonstrate the limitations of conventional dosimetry (2D) for the adjuvant brachytherapy treatment and assess whether tridimensional dosimetry relates more faithfully with the occurrence of adverse effect.

Methods: A prospective study in the Department of Radiation Oncology, Antonio Candido Camargo Cancer Center will be developed with an expected duration of 14 months and will include 60 patients. Dosimetric parameters of brachytherapy treatment of vaginal vault, able to influence the incidence of adverse effects will be evaluated. Computed tomography for planning of external beam radiotherapy and brachytherapy planning will be used, after placement of intra- vaginal applicator and urinary catheter. For planning brachytherapy two fast acquisition sequences, one with a urinary catheter not pulled and pulled another with the probe will be obtained. The prescription dose obey the standard indication of document of the International Commission on Radiation Units \& Measurements (ICRU 38).

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
60
Inclusion Criteria
  • Malignant neoplasm of the cervix or endometrium;
  • Tomography scan available in the planning system.
Exclusion Criteria
  • Patients did not undergo surgery as initial treatment;
  • Patients without available tomography for planning;

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
HDR Brachytherapy 24Gy (4 x 6Gy)2D HDR planningVaginal vault brachytherapy, associated or not with external beam radiotherapy.
HDR Brachytherapy 24Gy (4 x 6Gy)3D HDR planningVaginal vault brachytherapy, associated or not with external beam radiotherapy.
Primary Outcome Measures
NameTimeMethod
Dosimetry of Organs of genitourinary and gastrointestinal tractsone week after the tomograph

Dose in bladder; rectum; small intestine; sigmoid colon; urethra; dose trigone; vaginal cuff.

Secondary Outcome Measures
NameTimeMethod
Cost analysis with local care.6 weeks
Acute Genitourinary Toxicity6 weeks

toxicity associated with the genitourinary tract, using Common Terminology Criteria for Adverse Events v4.0 (CTCAE v4.0)

Acute Gastrointestinal toxicity6 weeks

toxicity associated with the gastrointestinal tract, using Common Terminology Criteria for Adverse Events v4.0 (CTCAE v4.0)

Late Genitourinary Toxicity3 Years

toxicity associated with the genitourinary tract, using Common Terminology Criteria for Adverse Events v4.0 (CTCAE v4.0)

Late Gastrointestinal toxicity3 Years

toxicity associated with the gastrointestinal tract, using Common Terminology Criteria for Adverse Events v4.0 (CTCAE v4.0)

Trial Locations

Locations (1)

AC Camargo Cancer Center

🇧🇷

São Paulo, SP, Brazil

© Copyright 2025. All Rights Reserved by MedPath